Roche Set For Disruptive Entry To MS Market With 'Brave' Ocrevus Pricing Strategy

Roche is taking no chances with its newly approved multiple sclerosis drug Ocrevus and has set a cost that ensures price is no barrier to treatment.

Multiple Sclerosis

Roche's is embarking upon a brave pricing strategy for its new multiple sclerosis drug Ocrevus (ocrelizumab) now that it has finally been licensed by the US FDA, following a slight technical hitch over manufacturing. The drug has been approved to treat both relapsing-remitting MS (RRMS) patients and the underserved primary progressive MS (PPMS) population and has been priced competitively.

The wholesale acquisition cost (WAC) has been set at $65,000, a "25% discount to [Pfizer Inc./Merck KGAA's] Rebif [interferon...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from New Products

More from Scrip

What Incyte Investors Expect From New CEO Bill Meury

 

Fresh from having sold Anthos to Novartis, the new CEO is expected to update the oncology and dermatology-focused firm's strategy.

Bayer Buoyant After EU Nod For Twice-Yearly Eylea

 
• By 

Green light follows a recent rejection by the US FDA to partner Regeneron's request for an extension to the dosing interval.

Executives On The Move: New CEO At Atalanta Therapeutics

Recent moves in the industry include C-suite changes at Atalanta Therapeutics and Climb Bio, plus seven companies get new CMOs.